Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

April 1, 2014

Primary Completion Date

September 22, 2017

Study Completion Date

August 24, 2023

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Olaparib

Olaparib bid

DRUG

Placebo

Placebo bid

DRUG

Abiraterone

Abiraterone 1000 mg

DRUG

Prednisone or prednisolone

Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.

Trial Locations (41)

2610

Research Site, Wilrijk

2650

Research Site, Edegem

4000

Research Site, Liège

7014

Research Site, Palma de Mallorca

11041

Research Site, Lake Success

14004

Research Site, Córdoba

17007

Research Site, Girona

21079

Research Site, Dijon

28050

Research Site, Madrid

30035

Research Site, Mirano

43100

Research Site, Parma

46010

Research Site, Valencia

49933

Research Site, Angers

56126

Research Site, Pisa

69373

Research Site, Lyon

73100

Research Site, Lecce

80131

Research Site, Napoli

92123

Research Site, San Diego

115478

Research Site, Moscow

125284

Research Site, Moscow

153040

Research Site, Ivanovo

197022

Research Site, Saint Petersburg

N6A 4G5

Research Site, London

J4V 2H1

Research Site, Greenfield Park

H2L 4M1

Research Site, Montreal

656 53

Research Site, Brno

656 91

Research Site, Brno

460 63

Research Site, Liberec

6815 AD

Research Site, Arnhem

6202 AZ

Research Site, Maastricht

6532 SZ

Research Site, Nijmegen

80-214

Research Site, Gdansk

02-781

Research Site, Warsaw

08916

Research Site, Badalona

08908

Research Site, L'Hospitalet de Llobregat

CF14 2TL

Research Site, Cardiff

EX2 5DW

Research Site, Exeter

M20 4BX

Research Site, Manchester

PL6 8DH

Research Site, Plymouth

TQ2 7AA

Research Site, Torquay

SS0 0RY

Research Site, Westcliff-on-Sea

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

AstraZeneca

INDUSTRY